In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 8, 1996, Pages 688-693

  Milatovic, D ^a   Wallrauch, C ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; MEROPENEM; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TITRIMETRY;

EID: 0029794360     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01691162     Document Type: Article

References (15)

1. Neu HC, Chin N: In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 1994, 38: 2615-2622.
2. Gooding BB, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 1993, 37: 349-353.
3. Ball P: Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. Journal of Antimicrobial Chemotherapy 1990, 26, Supplement F: 165-179.
4. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC Jr: In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy 1993, 37:366-370.
5. Spangler SK, Jacobs MR, Appelbaum PC: Activity of CP99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperaciliin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 1994, 38: 2471-2476.
6. Braveny I, Voeckl J, Machka K: Antimicrobial activity of netilmicin in comparison with gentamicin, sisomicin, tobramycin, and amikacin and their resistance patterns. Arzneimittel-Forschung 1980, 30: 491-495.
7. Gootz TD, Brighty KE, Anderson MR, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR: In vitro activity of CP99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl)naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease 1994, 19: 235-243.
8. Haller l: Comprehensive evaluation of ciprofloxacinaminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1985, 28: 663-666.
9. Bamberger DM, Peterson LR, Gerding DN, Moody JA, Fasching CE: Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model. Journal of Antimicrobial Chemotherapy 1986, 18: 51-63.
10. Haller I: Comprehensive evaluation of ciprofloxacin in combination with taeta-lactam antibiotics against Enterobacteriaceae and Pseudomonas aeruginosa. Arzneimittel-Forschung 1986, 36: 226-229.
11. Bustamente CI, Drusano GL, Wharton RC, Wade JC: Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomo-nas aeruginosa and other bacterial pathogens. Antimicrobial Agents and Chemotherapy 1987, 31: 632-634.
12. Moody JA, Gerding DN, Peterson LR: Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods. American Journal of Medicine 1987, 82: 44-54.
13. Rudin JE, Norden CE, Shinners EM: In vitro activity of ciprofloxacin against aerobic gram-negative bacteria. Antimicrobial Agents and Chemotherapy 1984, 26: 597-598.
14. Meyer RD, Liu S: Synergy studies in vitro of the effect of ciprofloxacin and selected beta-iactam agents and aminoglycosides upon multidrug-resistant Pseudomonas aeruginosa. Reviews of Infectious Diseases 1989, 11, Supplements: 1037.
15. Glamarellou H, Petrikkos G: Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1987, 31: 959-961.